A study uncovered a novel secondary acquired mutation, ALK F1174V, through comprehensive next-generation sequencing in an ALK-positive NSCLC patient who exhibited disease progression on crizotinib administration following an extended partial response (Ou et al., 2014). Here, ALK is linked to non-small cell lung carcinoma.